Loading
Verrica Pharmaceuticals Inc. Stock: price and insider trades · United States
4 insiders bought €182k of shares over the last 90 days, the latest filed 18 Aug 2026.
Verrica Pharmaceuticals Inc.: what insiders have been doing
Verrica Pharmaceuticals Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 12 filings were filed, from 5 insiders.
The flow runs one way only: 5 insiders bought (11 purchases totalling €5.7M) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 3 senior executives, 1 finance chief and 1 chief executive among the declarants. At €5.1M, the purchase published on 25 November 2025 by Manning Paul B is the largest of the period.
The data flag 10 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (18 August 2026) now reads 61 days. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 12 filings, this issuer sits below that mark. Since 2021, the database holds 30 purchases and 17 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 35.6 m USD and net income of -17.9 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
69
Thresholds
n/a
Buy Volume
€25M
30 ops. · all time
Sell Volume
€1M
17 ops. · all time
Who traded when
BuySaleJayson Rieger4 buys
Noah L. Rosenberg3 buys
David Zawitz2 buys
John J. Kirby2 buys
Paul B. Manning2 buys
Christopher G. Hayes1 sale
+1 other insider
Since the insiders bought
- -24.2%Entry US$4.99 · Close 15 Oct 2026 US$3.78
- -24.2%Entry US$4.99 · Close 15 Oct 2026 US$3.78
- -24.2%Entry US$4.99 · Close 15 Oct 2026 US$3.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,044 of 24,158 companies
28.5
score / 100
Value8
Quality49
FCF yld-27%
Earn yld-28%
EV/EBITDA·
ROE·
Gross mgn90%
Net mgn-50%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.78
Analyst consensus
6 analysts1.29/5
US$9.00Target US$13.83(+266%)US$20.00
Income statement
RevenueUS$35.6M
Gross profitUS$32.1M90% margin
EBITDA-US$9.4M-26% margin
Net income-US$17.9M-102.8% margin
Valuation
PER (forward)-2.6x
P/Book15.1x
Beta1.61
Balance sheet & cash
Market capUS$64.9M
Total debtUS$1.6M
Free Cash Flow-US$17.6M
Debt / Equity42%
Profitability & ownership
ROA-44.0%
% insiders49.0%
% institutions27.1%
Last declaration on 18 August 2026
Declarations69 total
20,000 shares@ US$5.060.13% mcap19.2% of flowCommon StockSEC:0002043558-26-000005:0
Canonical exit: 12 Nov 2026 (T+90)
5,000 shares@ US$4.910.032% mcap4.6% of flowCommon StockSEC:0002043558-26-000005:1
Canonical exit: 15 Nov 2026 (T+90)
4,200 shares@ US$4.910.027% mcap50.7% of flowCommon StockSEC:0001579649-26-000005:0
Canonical exit: 15 Nov 2026 (T+90)
2,030 shares@ US$4.920.013% mcap24.6% of flowCommon StockSEC:0001579649-26-000005:1
Canonical exit: 16 Nov 2026 (T+90)
6,000 shares@ US$4.980.039% mcap41.2% of flowCommon StockSEC:0002046750-26-000004:0
Canonical exit: 15 Nov 2026 (T+90)
5,000 shares@ US$4.930.032% mcap62.0% of flowCommon StockSEC:0001556327-26-000003:0
Canonical exit: 16 Nov 2026 (T+90)
10,000 shares0Common StockSEC:0001556327-25-000006:0
3,536 shares@ US$4.242538.0% of flowCommon StockSEC:0001556327-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
1,375,380 shares@ US$4.242531.7% of flowCommon StockSEC:0001494695-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
10,000 shares@ US$4.242558.8% of flowCommon StockSEC:0002046750-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
94,311 shares@ US$4.242576.1% of flowCommon StockSEC:0002043558-25-000003:0
Canonical exit: 23 Feb 2026 (T+90)
2,357 shares@ US$4.242524.7% of flowCommon StockSEC:0001579649-25-000004:0
Canonical exit: 23 Feb 2026 (T+90)
4,315 shares@ US$0.650.8% of flowCommon StockSEC:0001415889-25-008505:0
125,000 shares0Common StockSEC:0001415889-25-003233:0
125,000 shares0Common StockSEC:0001415889-25-003230:0
150,000 shares0Common StockSEC:0001415889-25-003232:0
50,000 shares0Common StockSEC:0001415889-25-003234:0
18,426,966 sharesCommon StockSEC:0001415889-24-027709:0
Canonical exit: 20 Feb 2025 (T+90)
280,898 sharesCommon StockSEC:0001415889-24-027711:0
Canonical exit: 20 Feb 2025 (T+90)
1,123,595 sharesCommon StockSEC:0001415889-24-027710:0
Canonical exit: 20 Feb 2025 (T+90)
54,267 shares0Common StockSEC:0001415889-24-026290:0
2,675,611.25 shares0Common StockSEC:0001415889-24-023835:0
9,888 shares@ US$2.6611.3% of flowCommon StockSEC:0001415889-24-022426:0
21,820 shares@ US$2.6650.7% of flowCommon StockSEC:0001415889-24-022424:0
25 of 69 declarations
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. is a U.S.-based dermatology therapeutics company listed on the NASDAQ in the United States under the ticker VRCA. Founded in 2013 and headquartered in West Chester, Pennsylvania, the company focuses on prescription treatments for skin diseases that require medical intervention. Its positioning is highly specialized, making it a niche player in medical dermatology rather than a broad-based pharmaceutical company.
Verrica’s core story centers on YCANTH® (VP-102), its lead marketed product. YCANTH is a proprietary drug-device combination containing cantharidin delivered through a single-use applicator designed for precise topical dosing. The company states that YCANTH is the first and only healthcare-professional-administered treatment approved by the FDA for molluscum contagiosum in adults and pediatric patients two years of age and older. That approval gives Verrica an important commercial and regulatory foothold in a market with limited approved options.
Read moreShow less
Beyond molluscum, Verrica is developing YCANTH/VP-102 for common warts, a larger dermatology segment with meaningful unmet need. The company has been advancing a global Phase 3 program in common warts with Torii Pharmaceutical, which also points to an international development and partnering strategy. Verrica is also advancing VP-315, an oncolytic peptide being evaluated for dermatologic oncology applications, including basal cell carcinoma. This pipeline broadens the company’s opportunity set beyond a single commercial product and gives it exposure to a second high-value dermatology franchise.
From a competitive standpoint, Verrica occupies a focused specialty niche. Its differentiation comes from FDA-approved product status, a device-enabled delivery system, and a pipeline aimed at indications where current treatment standards are not fully satisfactory. At the same time, the company operates in a challenging small-cap biotech environment, where execution risk, manufacturing quality control, reimbursement dynamics, and commercialization efficiency can materially affect performance.
Recent developments have been important. In February 2026, Verrica appointed a new Chief Commercial Officer, underscoring management’s focus on expanding YCANTH access and strengthening commercial execution. The company has also reported new clinical and regulatory progress for VP-315 and continued advancement of its common warts Phase 3 program. For investors, VRCA remains a high-risk, high-upside dermatology name whose thesis depends on commercial traction in the United States, potential international expansion, and continued pipeline validation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
